Your email has been successfully added to our mailing list.

×
0 0 0 0 0 0 0.026058631921824 0.0521172638436481
Stock impact report

FDA Clears Flex Pharma's FLX-787 to Commence US Phase 2 Trial in ALS Under IND

FLEX PHARMA (FLKS) 
Last flex pharma earnings: 8/1 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: ir.flex-pharma.com/investor-overview
Company Research Source: Business Wire
BOSTON--(BUSINESS WIRE)-- Click to Tweet this News Flex Pharma, Inc. (NASDAQ: FLKS), focused on developing treatments for cramps and spasms associated with the severe neurological diseases of amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS) and peripheral neuropathies such as Charcot-Marie-Tooth (CMT), today announced that the Company's investigational new drug (IND) application for FLX-787 for patients with ALS is effective which allows the Company to commence its U.S. Phase 2 clinical trial of FLX-787 in ALS patients who suffer from cramps as a consequence of the disease. The Company expects to begin enrolling US patients this summer in this randomized, controlled, double-blinded, parallel design study, referred to as the COMMEND trial. In addition, the Company has exploratory Phase 2 studies currently ongoing in patients with MS and ALS in Australia. FLX-787 is a small molecule co-act Show less Read more
Impact Snapshot
Event Time:
FLKS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for FLKS alerts
Opt-in for
FLKS alerts

from News Quantified
Opt-in for
FLKS alerts

from News Quantified